HOME >> BIOLOGY >> NEWS
Feinstein Institute and Cold Spring Harbor Lab join forces, seek manic depression genes

GLEN OAKS, NY -- Psychiatric researchers from The Zucker Hillside Hospital campus of The Feinstein Institute for Medical Research announced today they have launched a collaborative research project spearheaded by James Watson, PhD, the co-discoverer of the DNA double helix, and a team of researchers at Cold Spring Harbor Laboratory (CSHL) to identify key genetic underpinnings of bipolar disorder (BPD), a mental illness that is known to run in families. Expected to last two to three years, the study will focus on early-onset BPD and will involve children with the illness and their parents.

"For complex illnesses like bipolar disorder that vary dramatically in symptoms and severity among affected individuals, especially children and adolescents, identifying genetic underpinnings is very difficult," said Anil Malhotra, MD, lead investigator for The Feinstein. "It is also critical to accelerating and confirming a bipolar diagnosis and developing more rational and effective treatments. Collaborating with Cold Spring Harbor Laboratory will help make this a reality."

The collaboration will allow the team to leverage the unique clinical populations at Zucker Hillside, a renowned psychiatric hospital in Glen Oaks, NY, with state-of-the-art molecular tools available at CSHL in Cold Spring Harbor, NY, and The Feinstein Institute in Manhasset, NY.

Commonly referred to as manic depression, BPD is a mood disorder that goes beyond the day's ordinary ups and downs, becoming a serious medical condition and an important health concern in the United States. More than 2.3 million American adults are diagnosed with bipolar disorder, and research suggests that at least a quarter of a million children and adolescents are also affected by bipolar spectrum disorders, though some estimates are much higher. The disorder is characterized by periodic episodes of extreme elation, elevated mood or irritability (also called mania) countered by periodic depressive
'"/>

Contact: Christina Verni
cverni@nshs.edu
516-562-1232
North Shore-Long Island Jewish (LIJ) Health System
21-Dec-2006


Page: 1 2 3

Related biology news :

1. Feinstein researchers identify intelligence gene
2. Discovery at the Feinstein suggests new treatment approach for inflammatory conditions
3. Weizmann Institute scientists discover a control mechanism for metastasis
4. UCLAs California NanoSystems Institute partners with Abraxis BioScience
5. Wiley extends publishing partnership with the American Institute of Chemical Engineers
6. Biodesign Institute leads innovative project to prevent cancer
7. DOE Joint Genome Institute secures long-term lease on production genomics facility
8. Weizmann Institute scientists develop a general control switch for protein activity
9. Research without borders: Head of Santa Fe Institute to address NSF
10. Stowers Institutes Workman Lab demonstrates mechanism for decoding histone modification marks
11. The Institute of Ecosystem Studies recognized by the Wildlife Society

Post Your Comments:
(Date:5/21/2013)... shows that the nation,s land and water resources could ... up to 25 billion gallons of algae-based fuel a ... yearly needs. , The findings come from an in-depth ... to grow significant amounts of algae in large, specially ... May 7 issue of Environmental Science and Technology ...
(Date:5/21/2013)... Mo. Cancers of all types become most deadly ... Once cancer has reached this stage, it becomes very ... tumors that can develop. Now, researchers at the University ... nanoparticles that target lymphoma tumor cells wherever they may ... of oncology in the MU College of Veterinary Medicine, ...
(Date:5/21/2013)... is an uphill battle? Try staying fit in space, ... muscle and bone. , That,s the challenge a group ... new three-year, $1.2 million grant from NASA. Their goal ... exploratory missions. , "You could give astronauts the best ... them to stick to it, it isn,t going to ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4MU researchers develop radioactive nanoparticles that target cancer cells 2Fueling fitness on the final frontier 2
(Date:5/22/2013)...  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the ... LLP Microcap Conference, May 30, in New York, ... , CPA, Chief Financial Officer of Cleveland BioLabs, will ... at 1:30 p.m. Eastern Time.  A live and archived webcast ... page of the Cleveland BioLabs website at www.cbiolabs.com . ...
(Date:5/22/2013)... MN (PRWEB) May 22, 2013 ... Medical Supplies Pty Ltd are pleased to announce ... is the Australian and New Zealand distributor of DrugCheck® ... V8 Supercar Team participated in the Austin 400 May ... entered into an agreement that involves each car of ...
(Date:5/22/2013)... A recent study from researchers in Tasmania ... that those who took probiotics were able to run for ... showed that in extreme heat conditions, probiotics were able to ... acne treatment explains what this new discovery means for ... skin condition. , While researchers tote the benefits of ...
(Date:5/21/2013)... May 22, 2013 First patients ... of glycopyrronium bromide designed using Prosonix, particle engineering platform ... a portfolio of inhaled Respiratory Medicines by Design ... PSX1002 that will assess its effect on lung function ... patients with moderate to severe chronic obstructive pulmonary disease ...
Breaking Biology Technology:Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Australian Distributor of Express Diagnostics Signs Sponsorship Agreement with V8 Supercar Team 2Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4
Cached News: